INTRODUCTION
Evidence-based medicine has become essential to clinical and research actions since it was formally proposed in 1990. 1 The importance of evidence-based medicine concepts was highlighted in an article published in the British Medical Journal in 2007, in which the editors described the emergence of evidence-based medicine as one of the 15 most important milestones since the foundation of the British Medical Journal (1870). 2, 3 Henceforth, critical evaluation of evidence has become an important tool for assessing research quality and progress. Clinical research can be classified into levels of evidence, which are based on evaluating and interpreting evidence. The level of evidence is closely related to the likelihood that a piece of research will produce valid and reliable results.
Radiotherapy is no different in this regard. The pursuit of the best evidence is changing and is beginning to follow the trends reported in the 1990s. 4 As an example, conducting a quick Medline search associating "randomized trials" and "radiation oncology", 211, 144, 27 and 5 studies for the years 2012, 1996, 1981 and 1970 are identified, respectively. This finding demonstrates the evolution and intensification of research applied to radiotherapy, with a 40-fold increase in publications, over this time period.
Moreover, high-quality studies play a fundamental role in medical journals. From a broader perspective, the methodological quality and level of evidence of published articles are important determinants of how many times an article is cited, which therefore affects the impact factor of that journal and can also play a major role in the clinical transfer of knowledge. 5, 6 This has become an essential aspect of the evaluation of scientific journals. 6 In 2003, prominent journals began to use evidence hierarchies to rank the published studies. 7, 8 As a result, evidence-based medicine concepts were adopted by the conferences and symposia of the main specialties. Following this paradigm, great efforts have been applied within radiation oncology to follow the evidencebased medicine trend. Nevertheless, to date, there has been no systematic assessment of the quality of scientific production in several areas of radiation oncology.
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OBJECTIVE
The aim of this study was to identify central nervous system studies published in Radiotherapy & Oncology (Elsevier Ireland) over the last decade (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) , classify the type of study and evidence levels according to evidence-based medicine criteria and observe the inter-rater agreement in the classification of the studies included.
METHODS
Using electronic databases, two researchers independently evaluated all studies published in all editions of the major European radiation oncology-specific journal (Radiotherapy & were first reassessed using their abstracts and then by using their full texts. All studies relating only to dosimetry were excluded.
A third evaluator resolved any disagreements.
The studies thus identified were assessed by two examiners and were subsequently classified according to the methodological design: 1. systematic reviews; 2. randomized or non-randomized clinical trials; 3. cohort studies; 4. case-control studies; 5. case series; and 6. basic science studies. The studies were also classified according to their level of evidence using the guidelines of the Oxford Centre for Evidence-based Medicine: systematic reviews of randomized clinical trials, level I; randomized clinical trials, level II; cohort and case-control studies, level III; case series, level IV; and narrative reviews and other designs, level V. This is a widely used classification method that has been adapted for use within the radiation oncology literature. 9 This categorization was done after reading the full texts of the eligible studies.
For all the studies ultimately included, we also obtained information regarding the geographical location at which the study was performed, institutions/departments and authors involved in the publication, main condition studied, main disease investigated and time of publication. We also examined the productivity relating to radiotherapy for the central ner- 
Statistical analysis
The assumption of normal distribution in the sample was assessed using the Kolmogorov-Smirnov test. Cohen's kappa test was used to assess reliability and to evaluate the internal consis- The chi-square test was used to evaluate the proportions of papers at evidence levels I, II and III between the two periods. We considered P-values from two-sided tests < 0.05 to be statistically significant.
RESULTS
We identified 3,004 studies published over the 10-year period evaluated. Of these, 135 were initially selected (central nervous system disease), from which 10 were then excluded. Thus, 125 studies (4.2%) were considered eligible and were included in this analysis (Figure 1 ). There was an average of 300.4 publications per year during the study period (which included an average of 13.5 publications per year relating to the central nervous system). We noted an absolute increase in the number of published papers of 33% overall and 41% in relation to the central nervous system, from period 1 to period 2 ( Table 1) . Table 2 shows the distribution of the central nervous system studies according to the geographical location at which they were conducted. European studies accounted for more than 60% of the published data over the entire period and, in comparison with the rest of the world, this difference was statistically significant (P = 0.0306).
Stratification according to disease classification showed that the majority (74%) of the studies were related to central nervous system metastasis, followed by high-grade gliomas and benign tumors ( Table 2) .
We also noted that the average numbers of authors and departments involved in the studies were 6.86 and 3.29, respectively; 67% of the first authors were radiation oncologists ( were responsible for 40 published papers (32% of the total) and 78 institutions were responsible for the other 68% of publications over this 10-year period. Among these studies, 66.5% were case series (prospective and retrospective; number published (n) = 81 articles); 8% were prospective controlled studies (not randomized) (n = 10); 1% were cohort studies (n = 1); 1% were case-control studies (n = 1); 6% were cross-sectional studies (n = 8); and 3% were review articles (n = 5). Systematic reviews (n = 5) and randomized clinical trials (n = 7) accounted for approximately 10% of all the published papers. Other studies, which included case reports, were responsible for 5% of the publications (n = 7). In analyzing the level of 
DISCUSSION
In this 10-year single-journal analysis, we found that the studies published within the scope of the central nervous system increased in quality and number, although significant representation in the journal Radiotherapy & Oncology is still lacking (< 4.5% of published papers). We also found that case series (retrospective and prospective) represented the majority of central nervous system papers published in this journal.
Furthermore, level of evidence was found to be a reproducible tool, and secondary tumor (metastasis) research was well represented in this journal. The major strength of our data is that they represent, to the best of our knowledge, an original study with a representative period of evaluation in a single journal.
Moreover, this analysis was based on formal and systematic data-gathering and evaluation, and our results present sequential assessment, including formal statistical analysis and interreliability analysis based on Cohen's kappa test.
In the United States, according to the national database, primary central nervous system tumors account for less than 3% of all diagnosed neoplasms. 12 Similarly, primary and metastatic approximately 54% of all of them will require some radiation treatment during their lifetime, and 12% will require re-irradiation. 13 Based on evidence-based guidelines, the central nervous Others: radiologist, palliative care specialist, epidemiologist, nuclear medicine specialist, pediatrician and not specified. Abbreviations: HGG = high-grade glioma; LGG = low-grade glioma; Rad Onc = radiation oncologist; Clin Onc = clinical oncologist; Med Phys = medical physicist. Table 2 . Central nervous system papers published, according to region, diagnosis and first author over the 10-year period Table 1 . Frequencies of the hierarchy of evidence, grouped according to the period and region of origin system shows a highly recommended overall optimal radiotherapy utilization rate (approximately 92-93%). 13 In a comprehensive analysis in which the objective was to estimate the ideal proportion of patients with newly diagnosed central nervous system neoplasms who could benefit from external-beam radiotherapy, most of the recommendations were based on evidence level III. Similarly, it is important to note that level of evidence can be correlated with journal impact factor and that increasing numbers of studies with high-level evidence have been observed in palliative and orthopedic settings. 22, 25, 26 This finding emphasizes that there is an urgent need to expand the data relating to evidence-based oncology. The limitations of the current analysis lie in the fact that central nervous system articles may not be well represented in the journal chosen for analysis here because other radiation oncology journals that were not included in the electronic search also publish articles relating to the central nervous system. In addition, specific journals and higher-impact journals may account for significant numbers of published papers relating to the central nervous system. These were not assessed in the present analysis but may have had an impact on the data presented. Furthermore, a wider search of the literature might lead to a more optimistic outlook regarding the proportion of high-quality studies.
In this study, a training workshop on manuscript classification was conducted initially. The Oxford system of levels of evidence seemed to be a feasible instrument for evaluating studies, with a significant degree of consistency. 9 These findings and those in other studies emphasize the importance of specific training for individuals who are responsible for determinations relating to the quality of evidence. 28 Finally, our study represents a possible landmark for future studies and other evidence-based assessments on the central nervous system within the field of radiation oncology research. Moreover, the present study may result in new research opportunities, such as assessment of the internal and external validity of other study features and evaluations on high-impact and specialized journals. In particular, it would be interesting to evaluate how radiation oncologists manage and comprehend evidence-based medicine.
